Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. reports developments from a clinical-stage biotechnology business focused on vaccines and immunotherapies for infectious diseases and cancer. Recurring updates cover its MVA-based vaccine platform, the GEO-MVA candidate for mpox, smallpox and other poxviruses, GEO-CM04S1 as a multi-antigen COVID-19 vaccine, and Gedeptin as an oncolytic gene-directed therapy for solid tumors.
Company news also includes clinical-trial data reviews, government-supported program updates, patent activity tied to MVA-VLP technology and MUC1 tumor-associated antigen immunotherapy, financial results, and corporate presentations at healthcare and growth-company conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.